Sensitive cfDNA Biomarker Identification by Targeted Sequencing from Plasma and Urine Samples: A Comparative Study of a Large Patient Cohort​

Circulating cell-free DNA (cfDNA) profiling from blood plasma has demonstrated considerable potential for clinical applications in breast cancer, yet urinary cfDNA remains less explored. In a previous pilot study of plasma-derived and matching urinary cfDNA samples obtained from 15 presurgical triple-negative breast cancer patients, we have found plasma and urines may be complementary liquid biopsy samples for molecular profiling of tumor by targeted sequencing.